The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Xencor to Present at Upcoming Investor Conferences

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in the following upcoming investor events and conferences:

  • Bernstein CD28 Day

    Presentation: Monday, August 9, 1:00 p.m. ET (10:00 a.m. PT)
  • 2021 Wedbush PacGrow Healthcare Virtual Conference

    Panel: Tuesday, August 10, 1:10 p.m. ET (10:10 a.m. PT)
  • BTIG Virtual Biotechnology Conference 2021

    Presentation: Tuesday, August 10, 3:30 p.m. ET (12:30 p.m. PT)
  • Canaccord Genuity 41st Annual Growth Conference

    Presentation: Wednesday, August 11, 4:30 p.m. ET (1:30 p.m. PT)
  • Piper Sandler Virtual West Coast Bus Tour

    Presentation: Thursday, August 12, 4:00 p.m. ET (1:00 p.m. PT)

A webcast of the presentation at the Canaccord conference will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website approximately for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.